|
Patent landscape, scope, and claims: |
United States Drug Patent 5,860,419: Scope, Claims, and Landscape Analysis
United States Patent 5,860,419, granted on January 19, 1999, to The Regents of the University of California, covers a method of treating patients with elevated cholesterol levels. The patent's primary claim focuses on a method involving the administration of a specific gene therapy agent. The technology described aims to increase high-density lipoprotein (HDL) cholesterol levels. This analysis examines the patent's scope, its core claims, and the broader patent landscape surrounding this therapeutic approach.
What is the Core Technology Covered by Patent 5,860,419?
The patent is centered on a gene therapy approach to manage hypercholesterolemia. The method involves introducing genetic material into a patient to enhance the production or function of enzymes or proteins that facilitate the removal of low-density lipoprotein (LDL) cholesterol and the increase of HDL cholesterol. Specifically, the patent describes the use of viral vectors to deliver therapeutic genes.
The technology detailed in the patent targets the underlying biological mechanisms of cholesterol regulation. By modifying the genetic makeup of a patient's cells, the therapy aims to achieve a sustained improvement in lipid profiles, offering a potential alternative or adjunct to conventional pharmaceutical treatments. The viral vectors serve as delivery vehicles, ensuring the therapeutic gene reaches target cells where it can exert its intended effect.
What Specific Claims Does Patent 5,860,419 Encompass?
The patent's claims define the legal boundaries of the invention. Claim 1, the broadest independent claim, describes a method for treating hypercholesterolemia. This method involves:
- Administering to a mammal a viral vector comprising a gene encoding a functional sequence of human apolipoprotein A-I (apoA-I).
- The gene is expressed in the mammal.
- The expression results in an increased level of high-density lipoprotein (HDL) in the mammal.
Dependent claims further refine this method, specifying particular types of viral vectors, such as retroviral or adenoviral vectors, and detailing methods of administration, including systemic or localized delivery. For example, a dependent claim might specify a method of treating hypercholesterolemia by administering a retroviral vector containing the human apoA-I gene.
The claims are structured to protect the therapeutic use of apoA-I gene therapy for cholesterol management. The patent defines "hypercholesterolemia" as a condition characterized by elevated levels of LDL cholesterol or reduced levels of HDL cholesterol. The "functional sequence of human apolipoprotein A-I" refers to the genetic code that directs the synthesis of the apoA-I protein, which plays a critical role in reverse cholesterol transport.
What is the Scope of the Patent's Protection?
The scope of patent 5,860,419 extends to the therapeutic application of delivering the apoA-I gene via viral vectors to mammals, including humans, for the purpose of increasing HDL cholesterol and treating hypercholesterolemia. This protection encompasses:
- The Method of Treatment: The core of the patent lies in the method of using gene therapy for cholesterol management. This means any entity that practices this method, whether it involves developing the gene therapy, administering it, or offering it as a treatment, could be infringing.
- Specific Gene Delivery Systems: While the claims mention viral vectors generally, dependent claims may specify particular types. This broadens protection to various common viral vector systems used in gene therapy.
- Target Patient Population: The patent applies to mammals, clearly including humans, diagnosed with or at risk of hypercholesterolemia.
The patent does not claim the apoA-I gene itself, nor does it claim viral vectors in isolation. Its protection is specifically tied to the combination of delivering the apoA-I gene via viral vectors for the defined therapeutic outcome.
What is the Patent Landscape for ApoA-I Gene Therapy and HDL Augmentation?
The patent landscape for apoA-I gene therapy and methods to augment HDL cholesterol is complex and dynamic. Several entities, including academic institutions and pharmaceutical companies, have pursued research and patenting in this area.
Key Players and Their Technologies:
- The Regents of the University of California: The owner of patent 5,860,419, this institution was an early innovator in this field.
- Other Academic Institutions: Many universities have conducted research in gene therapy for cardiovascular diseases, leading to their own patent portfolios.
- Pharmaceutical and Biotechnology Companies: Major pharmaceutical companies have invested heavily in developing HDL-raising therapies, including gene-based approaches. These often involve strategies to increase apoA-I expression or function. Examples include companies exploring novel HDL mimetics, HDL infusion therapies, and other gene therapy vectors.
Key Themes in the Patent Landscape:
- ApoA-I Gene Variants and Analogues: Patents often claim modified versions of the apoA-I gene or engineered apoA-I proteins with enhanced stability or efficacy.
- Novel Gene Delivery Vectors: Beyond viral vectors, the landscape includes patents on non-viral delivery systems such as liposomes, nanoparticles, and exosome-based delivery.
- Combination Therapies: Patents may cover the use of apoA-I gene therapy in conjunction with other cholesterol-lowering drugs or treatments.
- Specific Indications: While patent 5,860,419 broadly covers hypercholesterolemia, subsequent patents may focus on more specific patient populations or disease subtypes, such as familial hypercholesterolemia or patients with cardiovascular disease.
- Methods of Production and Manufacturing: Patents also exist for the processes involved in producing and manufacturing gene therapy vectors and the resulting therapeutic products.
Patent Expirations and Generics:
Patent 5,860,419 is an older patent. The original term for U.S. patents granted after June 8, 1995, is 20 years from the filing date. Patent 5,860,419 was filed on January 23, 1997. Therefore, its 20-year term would have expired on January 23, 2017. However, patent term extensions can apply. If patent term extension (PTE) was granted for this patent due to regulatory review delays, its effective expiration date could be later. For patents related to pharmaceutical products, PTE can add up to five years to the patent term, with the possibility of an additional six months under certain conditions. Without explicit information on a PTE for this specific patent, the statutory expiration is 20 years from filing.
This means that the core claims of patent 5,860,419 are likely expired or nearing expiration. However, subsequent patent filings by The Regents of the University of California or other entities in related technologies would have created a layered patent protection strategy. This is a common practice where foundational patents are followed by patents covering improvements, new formulations, or new uses of the technology.
How Does Patent 5,860,419 Relate to Current HDL-Raising Therapies?
While patent 5,860,419's core claims may have expired, the underlying technology it protects laid the groundwork for subsequent research and development in HDL augmentation. Current HDL-raising therapies, whether pharmaceutical or investigational, often build upon the understanding of apoA-I's role.
Comparison with Current Approaches:
- Pharmaceuticals: Many HDL-raising drugs currently on the market or in development, such as CETP inhibitors (e.g., anacetrapib, dalcetrapib, evacetrapib – though some have faced setbacks), aim to increase HDL cholesterol levels by affecting HDL metabolism rather than directly by gene therapy. These drugs do not directly infringe on the method claims of patent 5,860,419.
- HDL Infusion Therapies: Some research has focused on infusing patients with HDL particles or recombinant apoA-I protein. These approaches also differ from the gene delivery method described in patent 5,860,419.
- Advanced Gene Therapy: More recent gene therapy research in cardiovascular disease may involve novel vectors, different therapeutic targets beyond apoA-I, or different delivery mechanisms. These would be protected by newer patents.
The significance of patent 5,860,419 lies in its early contribution to establishing the concept of using apoA-I gene therapy to raise HDL. Its expiration opens the door for broader application of the foundational technology, assuming no other intervening patents block specific implementations. However, any company developing a direct apoA-I gene therapy using viral vectors for HDL augmentation would need to conduct a thorough freedom-to-operate analysis, considering any remaining active patents in this field, including those that may claim specific viral vector constructs, modified apoA-I sequences, or improved delivery methods.
The patent landscape for HDL augmentation remains active, with ongoing innovation in understanding lipid metabolism and developing targeted therapies. Patent 5,860,419 represents a historical milestone in this evolving area.
Key Takeaways
- United States Patent 5,860,419 covers a method for treating hypercholesterolemia by administering a viral vector containing a gene encoding human apolipoprotein A-I (apoA-I) to increase high-density lipoprotein (HDL) levels.
- The patent's claims focus on the therapeutic method of gene delivery for cholesterol management.
- The patent term for 5,860,419, based on its filing date of January 23, 1997, would have expired 20 years later on January 23, 2017, absent any patent term extensions. This suggests the core claims are likely expired.
- The patent landscape for apoA-I gene therapy and HDL augmentation is populated by numerous patents from academic institutions and pharmaceutical companies, covering gene variants, novel delivery vectors, and combination therapies.
- While patent 5,860,419's core claims are likely expired, subsequent patents in related technologies necessitate a comprehensive freedom-to-operate analysis for any new apoA-I gene therapy development.
Frequently Asked Questions
-
Has patent 5,860,419 expired?
The statutory term of a U.S. patent is 20 years from the filing date. For patent 5,860,419, filed on January 23, 1997, this term expired on January 23, 2017. However, patent term extensions (PTE) may have been granted due to regulatory delays, which could extend the patent's expiration date. Without confirmation of PTE, the core claims are presumed expired.
-
What is apolipoprotein A-I (apoA-I) and why is it important for HDL?
ApoA-I is the primary protein component of high-density lipoprotein (HDL) particles. It plays a crucial role in reverse cholesterol transport, the process by which excess cholesterol is removed from peripheral tissues and transported back to the liver for excretion. Increasing apoA-I levels or function is a strategy to raise HDL cholesterol and potentially reduce cardiovascular risk.
-
Does patent 5,860,419 cover all gene therapies for cholesterol?
No, the patent specifically covers a method involving the administration of a viral vector to deliver the human apoA-I gene to increase HDL levels. It does not cover other gene therapy approaches that target different genes, use non-viral delivery systems, or aim to lower cholesterol through other mechanisms.
-
If the patent has expired, can anyone develop an apoA-I gene therapy today?
While the expiration of this foundational patent may allow for broader use of the core technology, a comprehensive freedom-to-operate analysis is essential. Numerous subsequent patents may cover specific improvements, variations in viral vectors, modified apoA-I sequences, or novel therapeutic applications, which could still pose infringement risks.
-
How does this patent relate to current HDL-raising drugs like statins or CETP inhibitors?
Patent 5,860,419 is for a gene therapy method. Statins primarily work by inhibiting cholesterol synthesis in the liver. CETP inhibitors work by blocking the cholesteryl ester transfer protein (CETP), which affects HDL and LDL metabolism. These pharmaceutical approaches operate via different mechanisms than the gene delivery method described in patent 5,860,419 and would not directly infringe on its claims, though they operate in the same therapeutic area.
Citations
[1] The Regents of the University of California. (1999, January 19). Method of treating mammals having elevated cholesterol levels. U.S. Patent 5,860,419. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
